Search
Trimetrexate
go.drugbank.com/drugs/DB01157ApprovedIt is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalA recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … It is the first in a new class of agents known as histone deacetylase inhibitors.
Janssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … Follow-up preclinical studies in rhesus monkeys[A220058] showed that the Ad26 vaccine produced a robust response and provided near perfect protection in nasal swabs and bronchoalveolar lavage following
Categories: Complex MixturesAlglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Poractant alfa
go.drugbank.com/drugs/DB09113ApprovedInvestigationalIt is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. … Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.
Categories: Complex MixturesRivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24HGatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnpatients taking gatifloxacin compared to those on macrolide antibiotics. … It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections.
Categories: Compounds used in a research, industrial, or household settingDithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032] … Dithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity.
Categories: Compounds used in a research, industrial, or household settingZenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833,A264843] Zenocutuzumab is also capable of promoting antibody-dependent cellular cytotoxicity in cancer cells.